BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15899811)

  • 1. Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo.
    Leyton J; Latigo JR; Perumal M; Dhaliwal H; He Q; Aboagye EO
    Cancer Res; 2005 May; 65(10):4202-10. PubMed ID: 15899811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
    Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
    Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
    Leyton J; Alao JP; Da Costa M; Stavropoulou AV; Latigo JR; Perumal M; Pillai R; He Q; Atadja P; Lam EW; Workman P; Vigushin DM; Aboagye EO
    Cancer Res; 2006 Aug; 66(15):7621-9. PubMed ID: 16885362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
    Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
    Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging.
    Leyton J; Lockley M; Aerts JL; Baird SK; Aboagye EO; Lemoine NR; McNeish IA
    Cancer Res; 2006 Sep; 66(18):9178-85. PubMed ID: 16982761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice.
    Sugiyama M; Sakahara H; Sato K; Harada N; Fukumoto D; Kakiuchi T; Hirano T; Kohno E; Tsukada H
    J Nucl Med; 2004 Oct; 45(10):1754-8. PubMed ID: 15471845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods.
    Kenny LM; Vigushin DM; Al-Nahhas A; Osman S; Luthra SK; Shousha S; Coombes RC; Aboagye EO
    Cancer Res; 2005 Nov; 65(21):10104-12. PubMed ID: 16267037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation status of thymidine kinase 1 following antiproliferative drug treatment mediates 3'-deoxy-3'-[18F]-fluorothymidine cellular retention.
    Sala R; Nguyen QD; Patel CB; Mann D; Steinke JH; Vilar R; Aboagye EO
    PLoS One; 2014; 9(7):e101366. PubMed ID: 25003822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models.
    Apisarnthanarax S; Alauddin MM; Mourtada F; Ariga H; Raju U; Mawlawi O; Han D; Bornmann WG; Ajani JA; Milas L; Gelovani JG; Chao KS
    Clin Cancer Res; 2006 Aug; 12(15):4590-7. PubMed ID: 16899606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice.
    Munk Jensen M; Erichsen KD; Björkling F; Madsen J; Jensen PB; Sehested M; Højgaard L; Kjær A
    PLoS One; 2012; 7(11):e50618. PubMed ID: 23226334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts.
    Jensen MM; Erichsen KD; Johnbeck CB; Björkling F; Madsen J; Bzorek M; Jensen PB; Højgaard L; Sehested M; Kjær A
    PLoS One; 2013; 8(1):e53410. PubMed ID: 23308217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
    Moroz MA; Kochetkov T; Cai S; Wu J; Shamis M; Nair J; de Stanchina E; Serganova I; Schwartz GK; Banerjee D; Bertino JR; Blasberg RG
    Clin Cancer Res; 2011 Mar; 17(5):1099-110. PubMed ID: 21245090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The uptake of 3'-deoxy-3'-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels.
    Barthel H; Perumal M; Latigo J; He Q; Brady F; Luthra SK; Price PM; Aboagye EO
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):257-63. PubMed ID: 15791434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
    Katz SI; Zhou L; Ferrara TA; Wang W; Mayes PA; Smith CD; El-Deiry WS
    Int J Oncol; 2011 Jul; 39(1):91-100. PubMed ID: 21537838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.
    Jensen MM; Erichsen KD; Björkling F; Madsen J; Jensen PB; Højgaard L; Sehested M; Kjær A
    PLoS One; 2010 Sep; 5(9):e12965. PubMed ID: 20885974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901.
    Leyton J; Smith G; Lees M; Perumal M; Nguyen QD; Aigbirhio FI; Golovko O; He Q; Workman P; Aboagye EO
    Mol Cancer Ther; 2008 Sep; 7(9):3112-21. PubMed ID: 18790789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
    Lee HJ; Oh SJ; Lee EJ; Chung JH; Kim Y; Ryu JS; Kim SY; Lee SJ; Moon DH; Kim TW
    Cancer Chemother Pharmacol; 2015 May; 75(5):1005-13. PubMed ID: 25776904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of 3'-deoxy-3'-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors.
    Yang YJ; Ryu JS; Kim SY; Oh SJ; Im KC; Lee H; Lee SW; Cho KJ; Cheon GJ; Moon DH
    Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):412-9. PubMed ID: 16404598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
    Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
    J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Depicts Heterogeneous Proliferation Pathology in Idiopathic Pulmonary Arterial Hypertension Patient Lung.
    Ashek A; Spruijt OA; Harms HJ; Lammertsma AA; Cupitt J; Dubois O; Wharton J; Dabral S; Pullamsetti SS; Huisman MC; Frings V; Boellaard R; de Man FS; Botros L; Jansen S; Vonk Noordegraaf A; Wilkins MR; Bogaard HJ; Zhao L
    Circ Cardiovasc Imaging; 2018 Aug; 11(8):e007402. PubMed ID: 30354494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.